Compare Marqeta Inc (MQ) vs Organon & Co. Common Stock (OGN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Marqeta Inc vs Organon & Co. Common Stock — how do they compare? Marqeta Inc trades at $18.39 (market cap $1.93B), while Organon & Co. Common Stock trades at $13.58 (market cap $3.62B). The key difference: Organon & Co. Common Stock is the larger of the two by market cap, and Organon & Co. Common Stock pays a 0.58% dividend while Marqeta Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Marqeta Inc for 44 Days and Organon & Co. Common Stock for 0 Days on average.
| MQ | OGN | |
|---|---|---|
Market Cap | $1.93B | $3.62B |
Volume | 915,027 | 2,892,999 |
Sector | Technology | Health |
52-Week High | $20.32 | $13.81 |
52-Week Low | $15.04 | $5.70 |
Typical Hold Time | 44 Days | 0 Days |
Enterprise Value | $1.25B | $11.04B |
Dividend Yield | — | 0.58% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Marqeta (MQ) trades at $18.18, down 0.6% on the day, with a bullish technical signal from moving averages. The company reported three consecutive quarterly earnings beats, with Q2 2026 showing 17% net revenue growth and GAAP profitability. Recent partnerships with BVNK for stablecoin cards and Google for kids' wallets highlight strategic expansion. Cash flow turned positive in 2025 at $86.42M, a significant improvement from prior years' losses.
Outlook is mixed: strong revenue growth and product initiatives support upside, but high P/E of 206.22 and thin net margin of 1.53% pose valuation risks. Analyst consensus is cautious with a $11.38 price target, well below current levels. Key risks include contract renewals in Q3 2026 and competitive pressures in fintech.
Organon (OGN) trades at $13.77, showing no change in the latest session. The stock demonstrates strong profitability with 52.68% gross margins and 24.04% ROE, though recent quarterly earnings have missed expectations. Valuation appears reasonable with P/E of 17.65 and P/S of 0.59. The company shows positive cash flow trends with 2026 projections indicating $533M net cash flow. Recent FDA developments for MIUDELLA and VTAMA products highlight ongoing pipeline progress.
OGN presents a mixed outlook with solid fundamentals offset by earnings misses. The healthcare company's improving cash flow and product pipeline offer potential upside, but investor sentiment remains divided with analysts showing cautious optimism. Key risks include execution challenges and competitive pressures in the pharmaceutical sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Marqeta Inc
Headquartered in Oakland, California, and founded in 2010, Marqeta provides its clients with a card-issuing platform that offers the infrastructure and tools necessary to offer digital, physical, and tokenized payment options without the need for a traditional bank. The company's open APIs are designed to allow third parties like DoorDash, Klarna, and Block to rapidly develop and deploy innovative card-based products and payment services without the need to develop the underlying technology. The company generates revenue primarily through processing and ATM fees for cards issued on its platform.
Read more on MQ →About Organon & Co. Common Stock
Organon & Co. is a global healthcare company focused on women's health, biosimilars, and established brands, spun off from Merck & Co. in 2021. Its portfolio of more than 70 medicines includes contraception and fertility therapies, immunology and oncology biosimilars, and treatments in cardiovascular, respiratory, and dermatology, distributed in over 140 countries.
Read more on OGN →
